These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36823302)

  • 1. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
    Mellinghoff IK; Lu M; Wen PY; Taylor JW; Maher EA; Arrillaga-Romany I; Peters KB; Ellingson BM; Rosenblum MK; Chun S; Le K; Tassinari A; Choe S; Toubouti Y; Schoenfeld S; Pandya SS; Hassan I; Steelman L; Clarke JL; Cloughesy TF
    Nat Med; 2023 Mar; 29(3):615-622. PubMed ID: 36823302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
    Mellinghoff IK; Penas-Prado M; Peters KB; Burris HA; Maher EA; Janku F; Cote GM; de la Fuente MI; Clarke JL; Ellingson BM; Chun S; Young RJ; Liu H; Choe S; Lu M; Le K; Hassan I; Steelman L; Pandya SS; Cloughesy TF; Wen PY
    Clin Cancer Res; 2021 Aug; 27(16):4491-4499. PubMed ID: 34078652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ivosidenib in Isocitrate Dehydrogenase 1
    Mellinghoff IK; Ellingson BM; Touat M; Maher E; De La Fuente MI; Holdhoff M; Cote GM; Burris H; Janku F; Young RJ; Huang R; Jiang L; Choe S; Fan B; Yen K; Lu M; Bowden C; Steelman L; Pandya SS; Cloughesy TF; Wen PY
    J Clin Oncol; 2020 Oct; 38(29):3398-3406. PubMed ID: 32530764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
    Mellinghoff IK; van den Bent MJ; Blumenthal DT; Touat M; Peters KB; Clarke J; Mendez J; Yust-Katz S; Welsh L; Mason WP; Ducray F; Umemura Y; Nabors B; Holdhoff M; Hottinger AF; Arakawa Y; Sepulveda JM; Wick W; Soffietti R; Perry JR; Giglio P; de la Fuente M; Maher EA; Schoenfeld S; Zhao D; Pandya SS; Steelman L; Hassan I; Wen PY; Cloughesy TF;
    N Engl J Med; 2023 Aug; 389(7):589-601. PubMed ID: 37272516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
    Lowery MA; Burris HA; Janku F; Shroff RT; Cleary JM; Azad NS; Goyal L; Maher EA; Gore L; Hollebecque A; Beeram M; Trent JC; Jiang L; Fan B; Aguado-Fraile E; Choe S; Wu B; Gliser C; Agresta SV; Pandya SS; Zhu AX; Abou-Alfa GK
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):711-720. PubMed ID: 31300360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
    Konteatis Z; Artin E; Nicolay B; Straley K; Padyana AK; Jin L; Chen Y; Narayaraswamy R; Tong S; Wang F; Zhou D; Cui D; Cai Z; Luo Z; Fang C; Tang H; Lv X; Nagaraja R; Yang H; Su SM; Sui Z; Dang L; Yen K; Popovici-Muller J; Codega P; Campos C; Mellinghoff IK; Biller SA
    ACS Med Chem Lett; 2020 Feb; 11(2):101-107. PubMed ID: 32071674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
    Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
    Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.
    Fan B; Chen Y; Yin F; Hua L; Almon C; Nabhan S; Cooper M; Yang H; Hossain M
    Clin Pharmacol Drug Dev; 2022 Apr; 11(4):429-441. PubMed ID: 35166065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH inhibition in gliomas: from preclinical models to clinical trials.
    Rudà R; Horbinski C; van den Bent M; Preusser M; Soffietti R
    Nat Rev Neurol; 2024 Jul; 20(7):395-407. PubMed ID: 38760442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
    Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting IDH1/IDH2 mutations in gliomas.
    de la Fuente MI
    Curr Opin Neurol; 2022 Dec; 35(6):787-793. PubMed ID: 36367045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new era after a long wait: Vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.
    Silvani A; Franceschi E
    Tumori; 2024 Jun; 110(3):160-161. PubMed ID: 38166539
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.
    Fan B; Abou-Alfa GK; Zhu AX; Pandya SS; Jia H; Yin F; Gliser C; Hua Z; Hossain M; Yang H
    Cancer Chemother Pharmacol; 2024 May; 93(5):471-479. PubMed ID: 38278871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vorasidenib- A Paradigm Shift in IDH1- or IDH2-Mutant Low-Grade Glioma Treatment.
    Malik H; Hudaib M; Rehman A
    J Pak Med Assoc; 2024 Oct; 74(10):1912-1913. PubMed ID: 39407401
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
    Fan B; Dai D; DiNardo CD; Stein E; de Botton S; Attar EC; Liu H; Liu G; Lemieux I; Agresta SV; Yang H
    Cancer Chemother Pharmacol; 2020 May; 85(5):959-968. PubMed ID: 32296873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ivosidenib and Azacitidine in
    Montesinos P; Recher C; Vives S; Zarzycka E; Wang J; Bertani G; Heuser M; Calado RT; Schuh AC; Yeh SP; Daigle SR; Hui J; Pandya SS; Gianolio DA; de Botton S; Döhner H
    N Engl J Med; 2022 Apr; 386(16):1519-1531. PubMed ID: 35443108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
    Fan B; Mellinghoff IK; Wen PY; Lowery MA; Goyal L; Tap WD; Pandya SS; Manyak E; Jiang L; Liu G; Nimkar T; Gliser C; Prahl Judge M; Agresta S; Yang H; Dai D
    Invest New Drugs; 2020 Apr; 38(2):433-444. PubMed ID: 31028664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib.
    Ellingson BM; Kim GHJ; Brown M; Lee J; Salamon N; Steelman L; Hassan I; Pandya SS; Chun S; Linetsky M; Yoo B; Wen PY; Mellinghoff IK; Goldin J; Cloughesy TF
    Neuro Oncol; 2022 May; 24(5):770-778. PubMed ID: 34751786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.
    Natsume A; Arakawa Y; Narita Y; Sugiyama K; Hata N; Muragaki Y; Shinojima N; Kumabe T; Saito R; Motomura K; Mineharu Y; Miyakita Y; Yamasaki F; Matsushita Y; Ichimura K; Ito K; Tachibana M; Kakurai Y; Okamoto N; Asahi T; Nishijima S; Yamaguchi T; Tsubouchi H; Nakamura H; Nishikawa R
    Neuro Oncol; 2023 Feb; 25(2):326-336. PubMed ID: 35722822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Mutant IDH Inhibitors in the Treatment of Glioma.
    Nakhate V; Lasica AB; Wen PY
    Curr Neurol Neurosci Rep; 2024 Dec; 24(12):631-643. PubMed ID: 39302605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.